Quick Answer
Vor Biopharma Inc. reported Diluted EPS of $70.50 per share (loss) for fiscal year 2025.
Vor Biopharma Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$70.50 | -107.2% |
| 2024 | -$34.03 | -1844.6% |
| 2023 | -$1.75 | +24.9% |
| 2022 | -$2.33 | -11.0% |
| 2021 | -$2.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$121.63 | -1410.9% | -868.4% |
| June 30, 2025 | -$12.56 | -2963.4% | -4730.8% |
| March 31, 2025 | -$0.26 | +42.2% | +96.8% |
| September 30, 2024 | -$8.05 | -1542.9% | -1863.4% |
| June 30, 2024 | -$0.41 | +8.9% | +8.9% |
| March 31, 2024 | -$0.45 | -4.7% | +8.2% |
| September 30, 2023 | -$0.49 | +22.2% | -8.9% |
| June 30, 2023 | -$0.45 | +22.4% | -4.7% |
- Vor Biopharma Inc. showed a decrease of -107.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Vor Biopharma Inc.’s diluted eps has declined by 3257.1% (from $2.10 per share (loss) to $70.50 per share (loss)).
- The most recent figure is from Vor Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: